pyrazines has been researched along with Long QT Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Ahmed, GF; Dota, CD; Ghiorghiu, D; Goldwater, R; Li, Y; Mellemgaard, A; Sahota, T; Verheijen, RB; Vik, T; Walker, S; Yan, W | 1 |
| Ahmed, GF; Harmer, AR; Sahota, T; Schalkwijk, S; Verheijen, RB | 1 |
| Bruderer, S; Darpo, B; Dingemanse, J; Hoch, M; Kaufmann, P; Remenova, T; Stoltz, R; Zhou, M | 1 |
3 trial(s) available for pyrazines and Long QT Syndrome
| Article | Year |
|---|---|
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Protein Kinase Inhibitors; Pyrazines; Triazines | 2021 |
Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses.
Topics: Double-Blind Method; Electrocardiography; Healthy Volunteers; Heart Rate; Humans; Inhibitory Concentration 50; Long QT Syndrome; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Pyrazines; Triazines | 2021 |
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Placebos; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult | 2015 |
1 other study(ies) available for pyrazines and Long QT Syndrome
| Article | Year |
|---|---|
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |